Literature DB >> 11498829

New cytotoxic agents and schedules for advanced breast cancer.

H J Burstein1, C A Bunnell, E P Winer.   

Abstract

Cytotoxic chemotherapy is important for treatment of women with hormone-insensitive or hormone-refractory advanced breast cancer. A variety of agents are effective, alone or in combination. The clinical activity and side effects of many agents, as well as principles for use of chemotherapy, are reviewed. Recent advances in chemotherapy for breast cancer include important studies on the role of dose-intensity, modifications of available agents to reduce side effects, and the availability of oral chemotherapeutics. Finally, the combination of chemotherapy with novel biological agents may improve outcomes for women with certain types of breast cancer. The growing availability of such biological therapies given in combination with chemotherapy may mean better survival in the future for women with advanced breast cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11498829     DOI: 10.1016/s0093-7754(01)90129-0

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  3 in total

1.  Doxorubicin and vinorelbine act independently via p53 expression and p38 activation respectively in breast cancer cell lines.

Authors:  A A Liem; M V C L Appleyard; M A O'Neill; T R Hupp; M P Chamberlain; A M Thompson
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

2.  A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer.

Authors:  Silverio Tomao; Adriana Romiti; Federica Tomao; Marisa Di Seri; Giuliana Caprio; Gian Paolo Spinelli; Edmondo Terzoli; Luigi Frati
Journal:  BMC Cancer       Date:  2006-05-24       Impact factor: 4.430

3.  Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines.

Authors:  N Prang; S Preithner; K Brischwein; P Göster; A Wöppel; J Müller; C Steiger; M Peters; P A Baeuerle; A J da Silva
Journal:  Br J Cancer       Date:  2005-01-31       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.